mal papilla cells: Possible involvement of sulfonylurea receptor
2B as a target of minoxidil.
J Invest Dermatol
2001; 117: 1594-
600.
31. Sakita S, Kagoura M, Toyoda M, Morohashi M. The induction by
topical minoxidil of increased fenestration in the perifollicular
capillary wall.
Br J Dermatol
1999; 140: 294-6.
32. Johnstone MA, Albert DM. Prostaglandin-induced hair growth.
Surv Ophthalmol
2002; 47: S185-202.
33. Messenger AG, Rundegren J. Minoxidil: mechanism of action on
hair growth.
Br J Dermatol
2004; 150: 186-94.
34. Price VH, Menefee E, Strauss PC. Changes in hair weight and hair
count in men with androgenetic alopecia, after application of 5%
and 2% topical minoxidil, placebo, or no treatment.
J Am Acad
Dermatol
1999; 41: 717-21.
35. Tosti A, Iorizzo M, Vincenzi C. Finasteride treatment may not pre-
vent telogen effluvium after minoxidil withdrawal.
Arch Dermatol
2003; 139: 1221-2.
36. Shear N. What we know so far about the new alopecia drugs.
Skin & Aging
1998; 27-29.
37. Sinclair R. Management of male pattern hair loss.
Cutis
2001;
68: 35-40.
38. Satoh H, Morikaw S, Fujiwara C, Terada H, Uehara A, Ohno R. A
case of acute myocardial infarction associated with topical use of
minoxidil (RiUP) for treatment of baldness.
Jpn Heart J
2000;
41: 519-23.
39. Price VH. Treatment of hair loss.
New Eng J Med
1999; 341:
964-973.
40. Trüeb RM. Causes and management of hypertrichosis.
Am J Clin
Dermatol
2002; 3: 617-27.
41. Moreno-Arias G, Castelo-Branco C, Ferrando J. Paradoxical effect
after IPL photoepilation.
Dermatol Surg
2002; 28: 1013-1016.
42. Bolduc C, Shapiro J. Management of androgenetic alopecia.
Am
J Clin Dermatol
2000; 1: 151-8.
43. García Bravo B, Sánchez Pedreño P, Camacho F. Eczema de con-
tacto por minoxidil.
Dermatitis de Contacto. Bol. Inform.
G.E.I.D.C.
1988; 13: 30.
44. Friedman ES, Friedman PM, Cohen DE, Washenik K. Allergic con-
tact dermatitis to topical minoxidil solution: Etiology and treat-
ment.
J Am Acad Dermatol
2002; 46: 309-12.
45. Olsen EA, Dunlap FE, Funicella T, Koperski JA, Swinehart JM,
Tschen EH, Trancik RJ. A randomized clinical trial of 5% topical
minoxidil versus 2% topical minoxidil and placebo in the treat-
ment of androgenetic alopecia in men.
J Am Acad Dermatol
2002; 47: 377-85.
46. Hagemann T, Schlutter-Bohmer B, Allan JP, Bieber T, Novak N.
Positive lymphocyte transformation test in a patient with allergic
contact dermatitis of the scalp after short-term use of topical
minoxidil solution.
Contact Dermatitis
2005; 53: 53-5.
47. Ross EK, Shapiro J. Management of hair loss.
Dermatol Clin
2005; 23: 227-43.
48. Camacho F. Alopecia, ¿curable o incurable? Editorial.
Med Clin
1992; 99: 100-2.
49. Camacho F. Aportación al estudio de las alopecias. En: Peyri J,
ed. Actualización en Dermatología
.
Madrid: Artes Gráficas
Palermo Ed, 1992; 89-104.
50. Camacho F, Mazuecos J. Avances en terapéutica dermatológica
1993.
Monogr Dermatol
1994; 7: 211-35.
51. Camacho F. Alopecias: Androgenética. Areata. Cicatriciales.
Monogr Dermatol
1993; 6 (num. extra): 79-104.
52. Baran R. Explosive eruption of pyogenic granuloma on the scalp
due to topical combination therapy of minoxidil and retinoic acid.
Dermatológica
1989; 179: 76-8.
53. Fisher AA. Unusual acute, nonallergic eruptions of the scalp from
combined use of minoxidil and retinoic acid.
Cutis
1993; 51: 17-
8.
54. Bouhanna P. Le minoxidil: 7 aspects particuliers dans sa prescrip-
tion.
Réalités thérapeutiques en Dermato-Vénéréologie
1992;
19: 14-7.
55. Bouhanna P. Le minoxidil: qu’en penser à l’heure actuelle?
Nouv
Dermatol
1991; 10: 24-34.
56. Ochoa BE, Sah D, Wang G, Stamper R, Price VH. Instilled bimato-
prost ophthalmic solution in patients with eyelash alopecia
areata.
J Am Acad Dermatol
2009; 61: 530-2.
57. Bikowski J, Lau EG, Jacob SE. Eyelash growth: a beneficial side
effect of prostaglandin analogues
. Cutis
2010; 85: 187-8.
58. Camacho-Martínez FM. Hypertrichosis and hirsutism. En
Bologna JL, Jorizzo JL, Rapini RP, eds. Barcelona: Mosby Ed,
2008: Dermatology 2008; 1007-18.
59. Law SK. Bimatoprost in the treatment of eyelash hypotrichosis.
Clin Ophthalmol
2010; 4: 249-58.
60. Dikici B, Bosnak M, Dagli A, Haspolat K. Interpheron alpha and
hypertrichosis of eyelashes.
Pediatr Infect Dis J
2002; 21: 448-
449.
61. Ozdogan M, Gur G, Kadayifcilar S, Boyacioglu S, Ozgur O, Teletar
H. An unusual adverse effect of interferon: hypertrichosis of the
eyelashes.
J Interferon Cytokine Res
2000; 20: 633-634.
62. Strober BE, Potash S, Grossman ME. Eyelash hypertrichosis in a
patient treated with topical latanoprost.
Cutis
2001; 67: 109-
110.
63. Johnstone MA. Hypertrichosis and increased pigmentation of
eyelash and adjacent hair in the region of the ipsilateral eyelids
of patients treated with unilateral topical latanoprost.
Am J Oph-
talmol
1997; 124: 544-7.
64. Demitsu T, Manabe M, Harina N, Sugiyama T, Moneda K,
Yamada N. Hypertrichosis induced by latanoprost.
J Am Acad
Dermatol
2001; 44: 721-3.
65. O’Toole L, Cahill M, O’Brien C. Eyelid hypertrichosis associated with
latanoprost is reversible.
Eur J Ophthalmol
2001; 11: 377-9.
66. Coronel-Pérez IM, Rodríguez-Rey EM, Camacho-Martínez FM.
Latanoprost in the treatment of eyelashes alopecia in alopecia
areata universalis
. J Eur Acad Dermatol Venereol
2010; 24: 481-
5.
67. Roseborough I, Lee H, Chwalek J, Stamper RL, Price VH. Lack of
efficacy of topical latanoprost and bimatoprost ophthalmic solu-
tions in promoting eyelash growth in patients with alopecia
areata.
J Am Acad Dermatol
2009; 60: 705-6.
68. Estève É, Beau-Salinas F, Esteve L, Lemacon J-M, Autret-Leca E,
Le Louet H, Hocine R, Wolkenstein P, Plaquet J-L. Mélanomes
associés au latanoprost: trois cas.
Ann Dermatol Venereol
2009;
136: 60-1.
69. Ojeda T, Camacho FM. Bimatoprost in the treatment of eye-
lashes alopecia in alopecia areata universalis
. Int J Trichol
2011
(en prensa).
70. Chartaux E, Joly P. Évaluation à long terme de l’efficacité du mét-
hotrexate seul ou associé à de faibles doses de corticoïdes dans
le traitement des pelades décalvantes totales.
Ann Dermato
Vénéréol
2010; 137: 507-13.
71. Bremmer S, van Voorhees AS, Hsu S et al. Obesity and psoriasis;
From the Medical Board of the National Psoriasis Foundation.
J Am Acad Dermatol
2010; 63: 1068-9.
72. Mortimer PS, Dawber PRP, Morris PS. Hypertrichosís and multi-
ple cutaneous squamous cell carcinomas ín association with
cyclosporine A carcinomas therapy.
J R Soc Med
1983; 76: 786.
73. Wysocki GP, Daley TD. Hypertrichosis in cyclosporine renal trans-
plant patients.
Clin Exp Dermatol
1987; 12: 191.
74. Shapiro J, Lui H, Tron V. et al. Systemic cyclosporine and low-
dose prednisone in the treatment of chronic severe alopecia are-
ata: a clinical and immunopathologic evaluation.
J Am Acad Der-
matol
1997; 36: 114-7.
75. Ferrando J, Grimalt R. Partial response of severe alopecia areata
to cyclosporine A.
Dermatology
1999; 199: 67-9.
76. MacDonald Hull SP, Wood ML, Hutchinson PE, Sladden M, Mes-
senger AG. Guidelines for the management of alopecia areata.
Br J Dermatol
2003; 149: 692-9.
77. Sweetman SC. Metoxaleno. Martindale. Guía completa de con-
sulta farmacoterapéutica. Barcelona, Pharma Ed, 2006; 424-7.
78. Litt JZ. Drug eruption. Referente manual 2000. New York.,
Parthenón Pub G. 2000.
79. Dawber RPR, Mortimer P. Hair loss during lithium treatment.
Br J
Dermatol
1982; 107: 124-125.
80. Brodin MB. Drug-related alopecia.
Dermatol Clin
1987; 5: 571-
9.
81. Gautam M. Alopecia due to psychotropic medications.
Ann Phar-
macother
1999; 33: 631-7.
82. Rushton DH. Nutritional factors and hair loss.
Clin Exp Dermatol
2002; 27: 396-404.
Monografías de
Dermatología
84
1...,77,78,79,80,81,82,83,84,85,86 88,89,90,91,92